For Brand Drugs, Doom And Gloom In 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
With sluggish pharmaceutical sales growth due to generic uptake, fewer patient visits to doctors and less use of chronic medications - 2010 was a dismal year for brand drugs, IMS data show.
You may also be interested in...
Bye Bye Lipitor: 2011 Presents A Big Opportunity For Generic Drugs
For the generic drug industry, 2011 is just about utopia, while for brand drug makers it marks the end of an era. With Pfizer's blockbuster statin Lipitor (atorvastatin) – the world's top-selling drug with more than $11 billion in sales – expected to go generic in the U.S. in November, it marks a symbolic shift from the blockbuster primary care glory days of the late 1990s to the highly genericized, highly fragmented market of today.
2010 Drug Launches: A Year Of Firsts Offers Hope For A Rebound
After several years of either niche or me-too drug launches, 2010 brought an encouraging wave of new molecular entities and novel biologics to market, including several first-in-class drugs addressing large therapeutic areas.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.